To main content

B-SMART - Brain-Specific, Modular and Active RNA Therapeutics

B-SMART - Brain-Specific, Modular and Active RNA Therapeutics

An Innovative nanotechnological RNA delivery systems targeting the direct cause of Alzheimer‘s disease instead of its symptoms. The overall objective of B-SMART is to design modular nanoparticles, to manufacture them via a quality-by-design protocol, and to achieve delivery of therapeutic RNAs to the brain and treat neurodegenerative diseases.

Neurodegenerative diseases such as Alzheimer's affect over 7 million people in Europe. Despite this fact, few treatments for this group of diseases are available so far. Nanomedical approaches can make a difference, providing new therapeutic options by helping drugs to enter the brain.

SINTEF Is a partner in the project.

Consortium:

  • UNIVERSITAIR MEDISCH CENTRUM UTRECHT, Netherlands (coordinator)
  • UNIVERSIDAD DE SANTIAGO DE COMPOSTELA, Spain
  • 20MED THERAPEUTICS BV, Netherlands
  • VIB, Belgium
  • THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD, United Kingdom
  • ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI SPA,Italy
  • SINTEF AS, Norway
  • MALVERN INSTRUMENTS LTD, United Kingdom
  • EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH, Germany

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 721058.

For more info on the project, see the web page http://b-smart-project.eu/

Published 09 November 2018
Vice President - Marketing

Project duration

01/01/2017 - 31/12/2021